Published on October 1, 2009 at 1:14 AM
Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it will present results from a Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the 2009 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.
Previously disclosed interim results will be updated to include final single-agent cohort data, as well as data demonstrating RDEA594’s ability to lower serum urate to less than 6.0 mg/dL in patients with mild to moderate renal insufficiency, which was the majority of patients randomized to RDEA594. In addition, the company will provide an update on improved drug formulations and will present data from a preclinical drug-drug interaction study demonstrating RDEA594’s potential to be used in combination with allopurinol and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen), both of which lower serum urate via a different mechanism of action than RDEA594.
Source: Ardea Biosciences, Inc.